<p><span><strong>Sabina Cerulová původně plánovala veterinu, ale náhoda, pandemie covid-19 a bakalářský projekt ji přivedly k výzkumu na RECETOXu. Dnes jako PhD studentka studuje vzácnou genetickou mutaci, která stojí za závažnými projevy u konkrétní pacientky, a pracuje s animálními modely, mikrobiomem i pokročilými zobrazovacími metodami. Ve vědě ji motivuje pestrost práce, možnost neustále se učit a naděje, že její práce jednou pomůže reálným lidem.&nbsp;</strong></span></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/RECETOX_MUNI_Ph_D_studentka_Sabina_Cerulova_Veda_da_strasne_moc_ale_strasne_moc_si_taky_vezme_Musi_vas_to_bavit_2_1ad2382856.jpeg" alt="RECETOX-MUNI: PhD studentka Sabina Cerulová: Věda dá strašně moc, ale strašně moc si taky vezme. Musí vás to bavit" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_RECETOX_MUNI_Ph_D_studentka_Sabina_Cerulova_Veda_da_strasne_moc_ale_strasne_moc_si_taky_vezme_Musi_vas_to_bavit_2_1ad2382856.jpeg 117w," sizes="100vw" width="738" height="984"></p><h5><strong>Jak ses dostala ke studiu biochemie a později k výzkumu na RECETOXu?</strong></h5><p><span>Na střední jsem chodila na gympl a dlouho jsem nevěděla, co přesně chci dělat. Až ve čtvrťáku jsem si uvědomila, že mě láká veterina. Jenže střední byla divoká – známky jsem měla dobré, ale moc jsem se neučila a myslela jsem si, že přijímačky budou podobné. Hodně jsem se spletla. Podala jsem si přihlášky na veterinu a na biochemii na PřF, kam jsem se naštěstí dostala a nastoupila jsem tam. Původně jsem plánovala další rok přestoupit na veterinu, ale přišel covid a tam se bralo podle průměru ze střední, většinou jen samé jedničky, takže jsem se nedostala. Ve druháku jsem začala pracovat na své bakalářce a tehdy se něco zlomilo – začalo mi to jít, víc jsem tomu rozuměla, známky se zlepšily a rozhodla jsem se bakaláře dokončit. A pak jsem dostala nabídku na skvělý projekt.&nbsp;</span></p><h5><strong>Ještě než přejdeme k onomu projektu, čemu ses věnovala v bakalářské práci?</strong><span>&nbsp;</span></h5><p><span>Bakalářku jsem dělala na analýzu mikrobiomu v kořenovém kanálku zubu u pacientů s apikální periodontitidou tady na RECETOXu u paní<strong> docentky Petry Bořilové Linhartové</strong>. Bylo to hrozně zajímavé – úplně nová práce, nové analýzy. Kvůli covidu bylo méně laboratorních cvičení, ale i tak jsem si to opravdu užila. Po bakaláři jsem dostala nabídku od paní docentky, protože věděla, že mě zajímají zvířata i veterina. V rámci zpracování diplomové práce mi nabídla onen již zmíněný projekt, na kterém spolupracujeme s <strong>Ústavem histologie a embryologie</strong>, se skupinou <strong>docenta Křivánka</strong>. Pracuje se tam s animálními modely, hlavně s myšmi, a studuje se vliv genetické mutace u konkrétní pacientky.&nbsp;</span></p><h5><strong>Proč tě zvířata tolik lákala? Neuvažovala jsi třeba o medicíně?&nbsp;</strong></h5><p><span>Ke zvířatům mám blízko odmalička – jezdila jsem na koni, doma jsme měli křečky, činčily, kočky, psy. Všichni se mě ptali, proč nejdu na medicínu, ale asi mám zvířata radši než lidi (smích). Lákala mě představa mít vlastní veterinární ordinaci, být jim blízko. Biochemie byla takový backup plán, ani jsem pořádně nevěděla, do čeho jdu. A nelituju. Veterina bude asi vždy sen, ale jsem ráda, že jsem zůstala tady.&nbsp;</span></p><h5><strong>Můžeš projekt přiblížit ještě o trochu víc? Pokud tomu rozumím správně, navazuješ vlastně na to samé téma i v rámci své dizertační práce?&nbsp;</strong></h5><p><span>Ano, je to tak. Naše výzkumná skupina spolupracuje s nemocnicí, od které jsme dostali výsledky pacientky, která měla od dětství spoustu patologických nálezů: léze na kostech, zkrácené kořeny v zubech, hypomineralizaci skloviny, bolestivost kloubů, vysoký fosfát v krvi. Udělala se jí kompletní analýza genů, na základě které jsme zjistili velmi vzácnou mutaci právě v genu, který studuji. Ve spolupráci s dalšími institucemi jsme vytvořili myšku se stejnou bodovou mutací, která prošla fenotypizačním screeningem a její projevy byly velmi podobné pacientce. To byl obrovský úspěch. Teď se snažíme model dál popisovat a do budoucna na něm testovat možnosti léčby – diety, úpravu DNA, cokoliv, co by mohlo pomoct nejen jí, ale i dalším pacientům s podobnými projevy.&nbsp;</span></p><h5><strong>Pracuješ tedy jen s jednou mutací, nebo i s dalšími modely?&nbsp;</strong></h5><p><span>Primárně se zaměřuji na jednu konkrétní bodovou mutaci, ale pracovali jsme i s knockout myšmi, kde je ten gen úplně vypnutý. Výsledky byly poměrně variabilní, takže se nakonec věnujeme oběma liniím. Zároveň díky spolupráci máme přístup i k datům z dalších myších modelů s mutacemi v genech úzce spojených s hyperfosfatémií, což nám pomáhá zasadit naše výsledky do širšího kontextu.&nbsp;</span></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/RECETOX_MUNI_Ph_D_studentka_Sabina_Cerulova_Veda_da_strasne_moc_ale_strasne_moc_si_taky_vezme_Musi_vas_to_bavit_1_787855e117.jpeg" alt="RECETOX-MUNI: PhD studentka Sabina Cerulová: Věda dá strašně moc, ale strašně moc si taky vezme. Musí vás to bavit" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_RECETOX_MUNI_Ph_D_studentka_Sabina_Cerulova_Veda_da_strasne_moc_ale_strasne_moc_si_taky_vezme_Musi_vas_to_bavit_1_787855e117.jpeg 117w," sizes="100vw" width="450" height="600"></p><h5><strong>Plánujete kromě modelu na zvířatech i výzkum u dalších pacientů?&nbsp;</strong></h5><p><span>Ano. Chceme udělat článek o dalších pacientech, hlavně o těch na dialýze, a podívat se na jejich fosfát a případné genetické modifikace. Fosfát se běžně nevyšetřuje, takže podobné poruchy mohou být skryté. Rádi bychom zjistili, jestli jejich problémy mohou souviset s tímto genem, a udělat tak náš projekt aplikovatelný na větší skupinu pacientů.&nbsp;</span></p><h5><strong>Používáte i zobrazovací metody? S jakým cílem?&nbsp;</strong></h5><p><span>Ano, chtěli jsme něco neinvazivního, protože microCT vyžaduje usmrcení myšky. Ve spolupráci s přístrojovým centrem testujeme MRI, abychom viděli projevy mutace v čase – kosti, měkké tkáně, ledviny. Získali jsme na to grant, zatím roční. Potřebujeme vidět progres a pak můžeme žádat o další finance.&nbsp;</span></p><h5><strong>Co tě nejvíc překvapilo na práci s animálními modely?&nbsp;</strong></h5><p><span>Čas. Všechno hrozně trvá. Myši jsou živé organismy – někdy se narodí a vzájemně se sežerou. Je to nepředvídatelné. A první šok přišel, když jsme čekali mláďata a nic se nedělo. Až pak jsme zjistili, že samci s touto mutací jsou neplodní. Jako milovnice zvířat jsem první myš oplakala. Pak se člověk ale vrátí k tomu, že to dělá pro pomoc pacientům. A hledá cesty, jak myší použít co nejméně.&nbsp;</span></p><h5><strong>Proč nepoužíváte raději </strong><i><strong>in vitro </strong></i><strong>přístupy, tedy testování mimo živý organismus?&nbsp;</strong></h5><p><span>Kvůli rychlosti a komplexnosti. Myši se rychle množí, dožívají se dvou let, mají 99 % genů stejných jako člověk. Na buňkách by to bylo mnohem pomalejší a neviděli bychom celkový obraz chování organismu.&nbsp;</span></p><h5><strong>Co tě na práci baví nejvíc?&nbsp;</strong></h5><p><span>Variabilita. To, že si můžu přizpůsobit den podle toho, na co mám kapacitu. Někdy dělám přípravu pro sekvenace, jindy analýzy, jindy výuku. Baví mě, že se pořád učím a že je to pestré.&nbsp;</span></p><h5><strong>Co je pro tebe na PhD studiu nejtěžší?&nbsp;</strong></h5><p><span>Time management. Jsem v tom slabší a za hodně vděčím své vedoucí, která mě usměrňuje. A taky to, že se nechci ztratit v práci – potřebuji mít osobní život. Dělám to, protože mě to baví, ale nechci se u toho zničit.&nbsp;</span></p><h5><strong>Jak vnímáš práci se studenty?&nbsp;</strong></h5><p><span>Baví mě to, ale je to náročné. Občas splynou studenti se mnou (smích), protože vypadám mladě. A jsou velmi motivovaní, někdy mám pocit, že ví víc než já. Ale hrozně mě to naučilo trpělivosti a sebevědomí. Přednášet mě moc baví.&nbsp;</span></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/RECETOX_MUNI_Ph_D_studentka_Sabina_Cerulova_Veda_da_strasne_moc_ale_strasne_moc_si_taky_vezme_Musi_vas_to_bavit_3_f7b11b8efa.jpeg" alt="RECETOX-MUNI: PhD studentka Sabina Cerulová: Věda dá strašně moc, ale strašně moc si taky vezme. Musí vás to bavit" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_RECETOX_MUNI_Ph_D_studentka_Sabina_Cerulova_Veda_da_strasne_moc_ale_strasne_moc_si_taky_vezme_Musi_vas_to_bavit_3_f7b11b8efa.jpeg 156w," sizes="100vw" width="450" height="450"></p><h5><strong>Na co jsi ve své dosavadní vědecké cestě nejvíc pyšná?&nbsp;</strong></h5><p><span>Na svůj progres. Nikdy jsem se neviděla v akademické sféře. Zpětně děkuju svým bakalářským konzultantkám za trpělivost. Změna přístupu a to, že mě to začalo bavit, mě posunulo nejvíc. Nejde mi o jeden konkrétní výsledek, ale o osobní růst.&nbsp;</span></p><h5><strong>Co tě motivuje pokračovat?&nbsp;</strong></h5><p><span>Vidina toho, že to jednou vyjde. Snažím se myslet pozitivně, i když jsou dny, kdy je to hodně těžké a nic nejde podle plánu.&nbsp;</span></p><h5><strong>Věnuješ se i popularizaci vědy?&nbsp;</strong></h5><p><span>Ano. Děláme toho hodně, hlavně pro děti. Nedávno jsem byla ve svém rodném městě v Karviné. Chodí k nám třeťáci, deváťáci… Je to skvělé, děti jsou nadšené. Popularizace je strašně důležitá – ukazovat, že věda je fajn a potřeba všude.&nbsp;</span></p><h5><strong>A co dál po doktorátu?&nbsp;</strong></h5><p><span>Nevím. Možná další doktorát (smích). Určitě bych ale chtěla zůstat ve vědě.&nbsp;</span></p><h5><strong>Jakou radu bys dala mladým lidem, kteří uvažují o vědecké dráze?&nbsp;</strong></h5><p><span>Musí je to bavit. Věda dá strašně moc, ale strašně moc si taky vezme. Člověk musí být nadšenec a najít si svoje téma.&nbsp;</span></p>

PhD studentka Sabina Cerulová: Věda dá strašně moc, ale strašně moc si taky vezme. Musí vás to bavit

<h4><strong>Srdečně Vás zveme na letošní Experientia Day!&nbsp;</strong></h4><p><strong>📍čtvrtek 18. června od 10 hodin v budově ÚOCHB AV ČR, Flemingovo nám. 2, Praha 6</strong></p><div><div><h5><strong>Co jsme pro vás přichystali za program? Můžete se těšit na:</strong></h5><p>🎓 vyhlášení nových stipendistek/stipendistů a držitele/držitelky start-up grantu<strong>&nbsp;</strong><a target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/experientia.cz?__cft__%5b0%5d=AZXpqJdct7ec4_UWm5mXewbM3TfIDfu8RHw2y21W2Pqnal1kbJ_pI6yaTGNjjmnmtpYtNd6GhcQZG_lgMo2IDcIjJzLL-3wX_SKn8qYOgObICJhHUniZECamJ7Y1UqqUWIDkbWLvecLQ7MXT_DIxdfkSJg1z1Tu_-3vekJMcfw_iOM5-hu23XWmKOnct3y45xp0&amp;__tn__=-%5dK-R"><strong>Nadace Experientia</strong></a><br>🎬 premiéru videa o výzkumné skupině <strong>Tomáše Fialy&nbsp;</strong>(MUNI), držitele start-up grantu pro roky 2026<span>–</span>2028<br>🔬 přednášku naší stipendistky pro rok 2022 <strong>Anny Poryvai</strong><span style="letter-spacing:0em;"> (EPFL, Švýcarsko &amp; ÚOCHB AV ČR) na téma: Caged Radicals and Uncaged Experience: Science and Life as a Postdoc</span><br><span style="letter-spacing:0em;">🧪 přednášku našeho stipendisty pro rok 2019 <strong>Rafaela Navrátila</strong> (PřF UK) na téma: Albertov Adventures: From Starting a Lab to Rethinking C–H Functionalization</span></p><p style="font-weight:400;">Přijďte, inspirujte se a setkejte se s našimi stipendisty a stipendistkami z celého světa</p><p style="font-weight:400;"><strong>Těšíme se na vás!</strong></p></div></div><div>&nbsp;</div>

Zveme vás na Experientia Day 2026

<p><strong>V týdnu od 20. dubna na Vás čekají v oblasti kapalné fáze a především HPLC a LC/MS následující webináře.</strong></p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://www.lcms.cz/webinars"><strong>👉 DETAILY A REGISTRACE V SEKCI WEBINÁŘE</strong></a></h4></blockquote><blockquote><p><strong>👉 Vyhledávejte a filtrujte v největší globální databázi</strong> s více než <strong>5 500 GC, HPLC, MS a spektroskopickými webináři.</strong></p></blockquote><h5><span><strong>1. Metrohm: Copper deposition baths: Advanced analytical solutions for development and monitoring</strong></span></h5><ul><li>Út, 21.4.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6123">Registrace</a></li></ul><p>Zjistěte, jak titrace, CVS, XRF a pH měření zlepšují kontrolu pokovovacích lázní, kvalitu dat a stabilitu výroby.</p><h5><span><strong>2. Bruker: Exploring the Caenorhabditis elegans lipidome in 4D</strong></span></h5><ul><li>Út, 21.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6106">Registrace</a></li></ul><p>Pokročilá kombinace LC, ion mobility a HRMS umožňuje detailní objev a charakterizaci lipidů v modelovém organismu.</p><h5><span><strong>3. Technology Networks: Episode 3: PFAS in Food – Addressing Contamination in the Food Supply Chain</strong></span></h5><ul><li>Út, 21.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6108">Registrace</a></li></ul><p>Webinář o výzvách analýzy PFAS v potravinách, regulacích a kontaminaci v komplexních matricích.</p><h5><span><strong>4. Agilent Technologies: Getting the Most from Your Agilent LCMS System</strong></span></h5><ul><li>Út, 21.4.2026 17:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/5740">Registrace</a></li></ul><p>Tipy pro údržbu, optimalizaci výkonu a zvýšení provozuschopnosti LC-MS systémů.</p><h5><span><strong>5. Thermo Fisher Scientific: Mass spectrometry strategies to power drug discovery</strong></span></h5><ul><li>Út, 21.4.2026 19:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6097">Registrace</a></li></ul><p>Přehled moderních MS strategií v chemoproteomice pro urychlení vývoje léčiv.</p><h5><span><strong>6. SCIEX: PFAS first steps: A roundtable for new analysts</strong></span></h5><ul><li>St, 22.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6103">Registrace</a></li></ul><p>Diskuze zaměřená na základy PFAS analýzy, workflow optimalizaci a regulatorní připravenost.</p><h5><span><strong>7. SelectScience: What’s in your hydrogen? Analytical toolkits for fuel purity analysis</strong></span></h5><ul><li>St, 22.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6055">Registrace</a></li></ul><p>Přehled analytických metod GC, GC-MS, IC a FTIR pro kontrolu čistoty vodíku.</p><h5><span><strong>8. Separation Science: Testing PFAS in Biosolids: From Sample Preparation to Interference Separation</strong></span></h5><ul><li>St, 22.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6124">Registrace</a></li></ul><p>Strategie pro spolehlivou analýzu PFAS v náročných matricích kalů a odpadních vod.</p><h5><span><strong>9. Thermo Fisher Scientific: Automated direct mRNA sequence mapping using online partial RNase T1 digestion and 2D LC-MS</strong></span></h5><ul><li>St, 22.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6110">Registrace</a></li></ul><p>Automatizovaný 2D LC-MS workflow pro rychlou a detailní charakterizaci mRNA.</p><h5><span><strong>10. SCIEX: Unlocking SCIEX OS software: automating acquisition, analysis, and 21 CFR part 11 compliance reporting</strong></span></h5><ul><li>St, 22.4.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6125">Registrace</a></li></ul><p>Zjistěte, jak automatizace a funkce softwaru SCIEX OS podporují efektivitu a integritu dat.</p><h5><span><strong>11. Thermo Fisher Scientific: From experts to applications: Screening protein-drug interactions with HT-PELSA</strong></span></h5><ul><li>St, 22.4.2026 19:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6098">Registrace</a></li></ul><p>Pokročilé strategie pro studium interakcí protein–léčivo pomocí MS a Orbitrap Astral.</p><h5><span><strong>12. Agilent Technologies: Pesticide Residues &amp; Fumigants Edition</strong></span></h5><ul><li>Čt, 23.4.2026 08:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/5955">Registrace</a></li></ul><p>Workflow LC-MS/MS a GC-MS/MS pro pesticidy, včetně QuEChERS a regulatorních požadavků.</p><h5><span><strong>13. Agilent Technologies: Enhancing Peptide and Oligonucleotide Analysis with Ultra Inert HPLC Technology</strong></span></h5><ul><li>Čt, 23.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6134">Registrace</a></li></ul><p>Jak ultra-inertní HPLC kolony zlepšují analýzu peptidů a oligonukleotidů.</p><h5><span><strong>14. Thermo Fisher Scientific: Chromeleon Admin Console III: Data management and automation</strong></span></h5><ul><li>Čt, 23.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6126">Registrace</a></li></ul><p>Správa dat a automatizace v Chromeleon CDS pro velká laboratorní prostředí.</p><h5><span><strong>15. Waters Corporation: Informatics series #31 Empower Advanced Custom Fields - Examples</strong></span></h5><ul><li>Čt, 23.4.2026 11:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/5923">Registrace</a></li></ul><p>Pokročilé funkce Empower pro reporting, validaci a automatizaci výpočtů.</p><h5><span><strong>16. Waters Corporation: A Multi-Residue Approach - Pesticides, Pharmaceuticals, and Personal Care Products</strong></span></h5><ul><li>Čt, 23.4.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6112">Registrace</a></li></ul><p>Multireziduální LC-MS přístup pro environmentální analýzu dle EU regulací.</p><h5><span><strong>17. Waters Corporation: Analysis of Glyphosate, Glyphosinate and AMPA in water without the need of derivatisation</strong></span></h5><ul><li>Čt, 23.4.2026 15:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/5926">Registrace</a></li></ul><p>Analýza glyfosátu bez derivatizace – efektivní a robustní workflow.</p><h5><span><strong>18. Thermo Fisher Scientific: Insights from an IC specialist: Are you using the right eluent?</strong></span></h5><ul><li>Čt, 23.4.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6127">Registrace</a></li></ul><p>Praktické tipy pro optimalizaci eluentů v iontové chromatografii.</p><h5><span><strong>19. Waters Corporation: Managing Process Performance in Stage 3 Process Validation: Regulatory Expectations for Continued Process Verification</strong></span></h5><ul><li>Čt, 23.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6060">Registrace</a></li></ul><p>Regulatorní požadavky na CPV a strategie pro řízení výkonu procesů.</p><h5><span><strong>20. Thermo Fisher Scientific: High-throughput activity based protein profiling - Systematic mapping of covalent drug-protein interactions on a proteome-wide scale</strong></span></h5><ul><li>Čt, 23.4.2026 19:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6099">Registrace</a></li></ul><p>Chemoproteomika pro mapování interakcí léčiv s proteiny na úrovni celého proteomu.</p><h5><span><strong>21. Agilent Technologies: Advancing and Characterizing Next-Gen Antibody Conjugates: Insights from BBB-Targeting Antibody Platforms</strong></span></h5><ul><li>Pá, 24.4.2026 08:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6128">Registrace</a></li></ul><p>Pokročilá charakterizace protilátkových konjugátů pomocí LC-QTOF a aplikace v cílení na BBB.</p>

Webináře LabRulezLCMS týden 17/2026

Webináře

Osobnosti

Věda a výzkum

Článek

Nejbližší akce

Centrum je samostatným ústavem Přírodovědecké fakulty Masarykovy univerzity, který realizuje výzkum, vývoj, výuku a expertní činnost v oblasti znečištění prostředí toxickými látkami. Předmětem zájmu jsou především perzistentní organické polutanty (POPs), polární organické látky, toxické kovy a jejich specie, přírodní toxiny (cyanotoxiny).

RECETOX - Centrum pro výzkum toxických látek v prostředí

Podporujeme mladé vědkyně a vědce z oboru organické, bioorganické a medicinální chemie na zahraničních stážích i zde v ČR díky tzv. start-up grantům Nadace Experientia.

Nadace Experientia

Vše ze světa analytické chemie na jednom místě. Propojujeme lidi při řešení jejich problémů. U nás naleznete všechny potřebné informace snadno, rychle a přehledně. Přestaňte hledat a začněte nacházet.

LabRulez

The Analytical Scientist

Bruker

Wiley

SCIEX

Evosep Biosystems

Waters Corporation

<p><strong>This online event has been designed for our customers and brings together opinion leaders, top scientists and industry innovators to share their research in the biopharma field.</strong></p>
<p>The technologies presented will be CE and LC-MS.</p>
<p>Agenda:</p>
<h5><strong>10:00–10:10 Welcome and introduction</strong></h5>
<ul>
<li>Steve Lock, SCIEX</li>
</ul>
<h5><strong>10:10–10:35 Use of LC-MS in process analytical testing as part of development of a continuous manufacturing workflow</strong></h5>
<ul>
<li>Daniel Myatt / Ronan Gough, CPI</li>
</ul>
<h5><strong>10:35–11:00 Tips and tricks for biotherapeutics characterization by peptide mapping</strong></h5>
<ul>
<li>Giulia Calloni, SCIEX</li>
</ul>
<h5><strong>11:00–11:25 Developing methods for SEC-MS and IEX-MS for the analysis of biotherapeutics</strong></h5>
<ul>
<li>Sarah Nguyen, Strasbourg University</li>
</ul>
<h5><strong>11:25–11:35</strong> Break</h5>
<h5><strong>11:35–12:00 The power of CZE analysis for characterization of NANOBODY® molecules</strong></h5>
<ul>
<li>Dries Dejaegere, Sanofi</li>
</ul>
<h5><strong>12:00–12:25 Multi-capillary gel electrophoresis to increase throughput for the purity analysis of biotherapeutic proteins</strong></h5>
<ul>
<li>Theresa Merlino, The Janssen Pharmaceutical Companies of Johnson &amp; Johnson</li>
</ul>
<h5><strong>12:25–12:50 A disruptive approach to the characterization of mAb charge variants during biopharmaceutical process development</strong></h5>
<ul>
<li>Greg Adams, FUJIFILM</li>
</ul>
<h5><strong>12:50–13:00 Wrap-up and Q&amp;A</strong></h5>
<blockquote>
<p><strong>Presenter:</strong> Steve Lock, PhD (Snr. Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)</p>
</blockquote>
<blockquote>
<p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p>
</blockquote>
<p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SCIEX_agenda_day_1_6818ee0331/SCIEX-agenda-day-1.jpg" alt="SCIEX - agenda day 1.jpg"/></p>


SCIEX: SCIEX Biopharma meeting - 3rd edition! Day 1 - Gene therapy, vaccines and oligonucleotides

SCIEX Biopharma meeting (Day 1) - Gene therapy, vaccines and oligonucleotides

Gene therapy, vaccines and oligonucleotides. The technologies presented will be CE and LC-MS.

Day 1 - Gene therapy, vaccines and oligonucleotides

<p><strong>This online event has been designed for our customers and brings  together opinion leaders, top scientists and industry innovators to share their research in the biopharma field.</strong></p>
<p>The technologies presented will be CE and LC-MS.</p>
<p>Agenda:</p>
<h5><strong>10:00–10:10 Welcome and introduction</strong></h5>
<ul>
<li>Steve Lock, SCIEX</li>
</ul>
<h5><strong>10:10–10:35 Particle seizing by CE</strong></h5>
<ul>
<li>Hervé Cottet, Montpellier University</li>
</ul>
<h5><strong>10:35–11:00 Application of CE for purity analysis in cell and gene therapy</strong></h5>
<ul>
<li>Ryan Hylands / Luiza Chrojan, Pharmaron</li>
</ul>
<h5><strong>11:00–11:25 Tips and tricks for success in CE analysis</strong></h5>
<ul>
<li>Whitney Smith, SCIEX</li>
</ul>
<h5><strong>11:25–11:35</strong> Break</h5>
<h5><strong>11:35–12:00 RNA payload analysis: development and analytical challenges</strong></h5>
<ul>
<li>Jérémie Parot, SINTEF Industry</li>
</ul>
<h5><strong>12:00–12:25 The use of CE for AAV analytics</strong></h5>
<ul>
<li>Padraig Flaherty, MeiraGTx</li>
</ul>
<h5><strong>12:25–12:50 Oligo analysis by LC-MS</strong></h5>
<ul>
<li>Alexandra Bushby, Labcorp</li>
</ul>
<h5><strong>12:50–13:00 Wrap-up and Q&amp;A</strong></h5>
<blockquote>
<p><strong>Presenter:</strong> Steve Lock, PhD (Snr. Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)</p>
</blockquote>
<blockquote>
<p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p>
</blockquote>
<p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SCIEX_agenda_day_2_b442145213/SCIEX-agenda-day-2.jpg" alt="SCIEX - agenda day 2.jpg"/></p>


SCIEX: SCIEX Biopharma meeting - 3rd edition! Day 2 - Therapeutic proteins and peptides

SCIEX Biopharma meeting (Day 2) - Therapeutic proteins and peptides

Therapeutic proteins and peptides. The technologies presented will be CE and LC-MS.

Day 2 - Therapeutic proteins and peptides

<p><strong>Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!</strong></p>
<p>Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. </p>
<p>We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. </p>
<p>Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. </p>
<p>The event will have three parts: </p>
<ul>
<li><p><strong>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).</strong></p>
</li>
<li><p><strong>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).</strong></p>
</li>
<li><p><strong>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Day Powell (Environmental Application Specialist , Agilent)</p>
</blockquote>
<blockquote>
<p>Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.</p>
</blockquote>
<blockquote>
<p>Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Marcus Chadha (EMEA Applications Specialist Manager, Agilent)<br/>Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.</p>
</blockquote>
<blockquote>
<p>In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.</p>
</blockquote>
<blockquote>
<p>He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)</p>
</blockquote>
<blockquote>
<p>Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.</p>
</blockquote>
<blockquote>
<p>His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)</p>
</blockquote>
<blockquote>
<p>Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.</p>
</blockquote>
<blockquote>
<p>Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.</p>
</blockquote>
<blockquote>
<p>She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.</p>
</blockquote>


Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5><strong>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</strong></h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5><strong>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</strong></h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</strong></h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5><strong>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</strong></h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 2: Thursday, October 26</h3>
<h5><strong>10:00 - 10:40 Case studies from bioanalytical lab in DMPK, Syngene: SCIEX 7500 system and beyond</strong></h5>
<ul>
<li>Ashwani Gaur (Syngene International Ltd)</li>
</ul>
<h5><strong>10:40 - 11:20 Challenges in quantification of NDSRI’s</strong></h5>
<ul>
<li>Dama Venugopal Rao (Dr. Reddy&#39;s Laboratories)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Nitrosamine impurities in dermal products: from APIs and their salts (secondary amines) evaluations through analytical chemistry and mass spectrometry</strong></h5>
<ul>
<li>Emiliano de Dominicis (Merieux)</li>
</ul>
<h5><strong>12:10 - 12:50 Extractables and leachables assessments in biologics manufacturing</strong></h5>
<ul>
<li>Lukas Mogler (Lonza)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 2)

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces.</strong></p>
<p>MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: </p>
<ul>
<li>Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</li>
</ul>
<h4>Part Three – October 31st, 2023: Building an MS Imaging Facility</h4>
<p><strong>In the final session of the series, we will have a roundtable with Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) where we will discuss the steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.</strong></p>
<blockquote>
<p><strong>Presenter:</strong> Roy Martin (Principal Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Dr. LeRoy B. Martin, III is the Principal Field Marketing Manager for Biological Mass Spectrometry at Waters Corporation. His primary role is developing and promoting advanced mass spectrometry solutions in the Americas. He is also charged with evaluating and integrating new technologies and methods in collaborations and product development. Most recently, his focus has been on molecular imaging mass spectrometry and implementation of advances in ion mobility technology. Other research interests include complex mixture quantitative proteomics and structural biology using mass spectrometry. Roy received a BS in Chemistry from Davidson College and a Ph.D. in Analytical Chemistry from North Carolina State University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ryan Leib (Director of Research, Stanford University Mass Spectrometry Laboratory)</p>
</blockquote>
<blockquote>
<p>Ryan Leib is Director of Research for the Stanford University Mass Spectrometry Laboratory. Ryan received his B.S. in Biochemistry from the University of Tulsa (Tulsa, OK), with a focus on LC/MS methods development for natural products discovery. In 2010, he received his Ph.D. in Chemistry from the University of California at Berkeley investigating ionic cluster formation and energetics in Professor Evan Williams’ mass spectrometry laboratory. Prior to joining SUMS in 2014, Ryan developed mass spectrometric analyses for complex mixtures as a Project Leader at SRI International, a non-profit contract R&amp;D firm based in Silicon Valley.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: Building an MS Imaging Facility

Building an MS Imaging Facility

The steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.

<p><strong>During drug metabolite identification (Met ID) studies collision-induced dissociation (CID) is the most commonly used fragmentation technique for LC-MS experiments.</strong></p>
<p>Many conjugation metabolites are found to have multiple bonding potentials to parent drugs. It is a great challenge to locate the bonding sites by CID due to the information lost by highly selective cleavage on these bonds. </p>
<p>The novel electron-activated dissociation (EAD) is a recently developed technology on the SCIEX ZenoTOF 7600 system. From a single LC-MS/MS experiment CID and EAD data can be collected, providing information rich fragmentation spectra. The additional information can help in confident localization and identification of metabolites compared to CID alone. These fragments can be crucial to locate the metabolic modification sites, such as conjugations. </p>
<p>In this study, the application of EAD in drug metabolite profiling is explored. The efficiency in the structural elucidation of conjugation metabolites is compared with that of CID.</p>
<p>Webinar Learning Objectives:</p>
<ul>
<li><p><strong>Learn how EAD can be advantageous in confident identification and localization of drug metabolites</strong></p>
</li>
<li><p><strong>Discover the sensitivity of the Zeno trap technology in the identification of the low abundant metabolites</strong></p>
</li>
<li><p><strong>Explore the capabilities of the Molecule Profiler software in processing EAD and CID data for drug metabolite identification</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Ming Yao (Principal Scientist, CPPDB, Bristol-Myers Squibb)</p>
</blockquote>
<blockquote>
<p>Ming Yao currently works at Bristol-Myers Squibb (BMS). He received his B.Sc. from Henan University, and his M.Sc. from the Chinese Academy of Preventive Medicine China. After graduation, he worked at the Institute of Occupational Medicine as an associate professor.</p>
</blockquote>
<blockquote>
<p>As a visiting Associate Professor, he conducted research for bioactivation of chemicals at Merck as well as the University of Western Ontario. After then, he joined BMS and he was responsible for designing and conducting in vitro and in vivo biotransformation studies for multiple programs to support both development and discovery projects. Most recently, he has also been involved in the development of protein drugs, such as the antibody drug conjugates (ADCs) and biotransformation of biologics.</p>
</blockquote>
<blockquote>
<p>Ming has over 28 years of experiences in the pharmaceutical industry and has over 50 publications and 5 book chapters covering new technologies of mass spectrometry and its applications in drug metabolism.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Rahul Baghla (Manager Pharma Applications, SCIEX)</p>
</blockquote>
<blockquote>
<p>Rahul Baghla, Manager Pharma Applications is a research scientist with 12+ years of experience in various applications of mass spectrometry delivering in Pharma/Biopharma/CRO industries. He is specialised in implementing new mass spectrometry technologies in bioanalytical/analytical method development/validation, drug discovery, ADME assays and clinical studies.</p>
</blockquote>
<blockquote>
<p>He has supported various functions within pharma industry including nutrition, wellness, and oral care based clinical trial studies over the years. Rahul has master’s degree in pharmaceutical analysis, master’s in business administration and a professional diploma in clinical research.</p>
</blockquote>
<blockquote>
<p>He is responsible for continuous engagement with pharmaceutical community to identify major analytical challenges, provide solutions and to find significant analytical opportunities for SCIEX.</p>
</blockquote>


SCIEX: Discover how Bristol-Myers Squibb uses electron-activated dissociation (EAD) to confidently identify drug metabolites and localize site of metabolism.

Discover how Bristol-Myers Squibb uses electron-activated dissociation (EAD) to confidently identify drug metabolites and localize site of metabolism.

Learn how EAD can be advantageous in confident identification and localization of drug metabolites.

LC/MS EAD & drug metabolites & localization of metabolism

<p><strong>Over the last few years, spatial biology has refined the understanding of coordinated biological processes that govern how systems both thrive and become vulnerable to disease.</strong></p>
<p>The latest tools offer advanced images that track the location and types of proteins and RNA across tissue microdomains and cellular phenotypes using a variety of detection techniques but lack the ability to see other post-transcriptional processes defined by metabolites and glycans. MALDI Imaging is a true multiomics technique that allows for spatial determination of metabolites and lipids in tissue, as well as expanding targeted analysis to small molecules, glycans, and proteins. The addition of MALDI-2 and microGRID technology enables imaging for maximum biological information at previously unreachable sensitivity and robust (sub)cellular resolution.</p>
<p>This webinar will introduce how Bruker’s new MALDI HiPLEX-IHC Imaging workflow delivers greater speed and field-of-view for multiplexed protein imaging in tissue, while providing thousands of untargeted molecular images that enable deeper tissue subtyping. The combination of protein spatial localization combined with metabolites and glycans offers a new pathway for coordinated biomarker discovery to complement existing spatial techniques.</p>
<p>What to expect?</p>
<ul>
<li><strong>Live presentation from Bruker’s experts to see ease of use of the timsTOF fleX platform, new MALDI HiPLEX-IHC workflows and highlighting user stories, including focus on improved spatial resolution with microGRID, improved sensitivity with MALDI-2, improved separation selectivity with trapped ion mobility and comprehensive software solutions</strong></li>
</ul>
<p>Who should attend?</p>
<ul>
<li><p>Anyone using or interested in using tools for spatial biology discovery or translation</p>
</li>
<li><p>Scientists &amp; researchers interested in expanding their workflows to the spatial dimension, scientists working with spatial distribution of small molecule biologics</p>
</li>
<li><p>MALDI Imaging users wanting to expand their workflows</p>
</li>
<li><p>Anyone interested in learning more about MALDI Imaging capabilities</p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Kate Stumpo, Ph.D. (Senior Market Manager Imaging, Bruker, Billerica, MA, USA)</p>
<ul>
<li>Introduction and welcome to MALDI Imaging </li>
<li>Spatial biology meets Mass Spectrometry in cancer research </li>
<li>MALDI Imaging utility in neurological research</li>
</ul>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Corinna Henkel, Ph.D. (Application Scientist Imaging, Bruker, Bremen, Germany)</p>
<ul>
<li>MALDI HiPLEX-IHC workflow technical introduction</li>
<li>Software solutions for multiomics integration</li>
</ul>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Bjoern Wendik, Ph.D. (Business Development Manager, Bruker, Bremen, Germany)</p>
<ul>
<li>Bridging non-MS imaging to the MALDI world</li>
<li>Automation, workflow and relevance for future clinical applications</li>
</ul>
</blockquote>


Bruker: Redefining Hiplexed Spatial Multiomics

Redefining Hiplexed Spatial Multiomics

How Bruker’s new MALDI HiPLEX-IHC Imaging workflow delivers greater speed and field-of-view for multiplexed protein imaging in tissue.

<p><strong>This webinar is your guide to get started with a fast and efficient, automated sample preparation protocol on the Opentrons OT-2.</strong></p>
<p>Utilize protein aggregation capture (PAC) on magnetic microparticles in an end-to-end  standardized and hands-off workflow, starting from protein lysate or plasma to peptide loaded on Evotips.</p>
<h4>Why choose an automated workflow?</h4>
<p>Automated sample preparation workflows have become a popular tool in proteomics laboratories for a number of reasons. With increased sample throughput on the Evosep One, you can prioritize numerous technical and biological replicates, adding robustness to downstream bioinformatic analyses.</p>
<p>By adopting full automation, you can gain precise control over protocols, ensuring reproducibility across samples and experiments. This minimizes batch effects, resulting in more reliable data for analysis and interpretation.</p>
<p>Furthermore, enhanced automation significantly reduces manual labor, enhancing reproducibility and providing researchers with more time for critical decision-making. This workflow also proves cost-efficient for large-scale applications, optimizing protein input for digestion.</p>
<h4>AUTOMATED WORKFLOW FOR INTEGRATED SAMPLE DIGESTION AND EVOTIP LOADING FOR HIGH-THROUGHPUT CLINICAL PROTEOMICS</h4>
<blockquote>
<p><strong>Presenter:</strong> Anders H.Kverneland (MD &amp; Postdoctoral researcher at Center for Cancer Immune Therapy, Herlev hospital)</p>
</blockquote>
<p>Protein identification and quantification is an important tool for biomarker discovery. With the increased sensitivity and shortened the analysis tim​e of modern mass spectrometers, sample-preparation remains a bottleneck and source of variability when studying large cohorts. To address this issue, we evaluated the use of a simple integrated workflow on the Opentrons OT-2 robot enabling both sample digestion and Evotip loading. Our results demonstrate high sensitivity combined with both reproducibility and stability even with very low sample inputs. The integration of the digestion and Evotip loading also strongly reduced the amount of reagents needed for the sample preparation. Using the integrated workflow, we evaluate the effects of cancer immune therapy on the plasma proteome in metastatic melanoma patients.</p>
<h4>STANDARDIZED AND FULLY AUTOMATED DEEP PROTEOME PROFILING OF PLASMA INTEGRATED WITH EVOSEP ONE ENABLES LARGE-SCALE CLINICAL COHORT ANALYSIS</h4>
<blockquote>
<p><strong>Presenter:</strong> Dorte Becker-Jensen (Application Manager at Evosep)</p>
</blockquote>
<p>This streamlined end-to-end workflow enables deep plasma profiling through the automated enrichment of membrane-bound vesicles and depletion of abundant proteins from a mere 4 μl of plasma. Integrated with the SCIEX ZenoTOF, it consistently identifies more than 3,500 protein groups, all with the ease of processing 30 samples per day at the push of a button.</p>


Evosep: Elevate efficiency: The power of automation

Elevate efficiency: The power of automation

Get started with a fast and efficient, automated sample preparation protocol on the Opentrons OT-2.

<p><strong>In this webinar, we will present end-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.</strong></p>
<p>A broad portfolio in sample prep automation for protein therapeutics allows for highly reproducible results in the starting point of the analysis. A broad range of consumables and columns will be presented, leading into the subsequent separation via HPLC and detection by mass spectrometry.</p>
<p>The 6545XT AdvanceBio was particularly developed for intact protein analysis, and the ultra-high vacuum and large molecule autotune led to excellent sensitivity in denatured and native applications, allowing quantitation on the intact protein level as well as ADR calculations. Peptide mapping and glycan analysis results, along with the confirmation of oligonucleotide sequences using Q-TOF-based workflows, will be presented.</p>
<p>We will also highlight the ultrahigh performance of the novel 6495 triple quadrupole LC/MS system (G6495D) with MassHunter Workstation 12.1 for comprehensive multiplexed protein quantification. Artificial intelligence (AI)-based SWARM autotune and enhanced system features provide seamless protein quantification method optimization, ultimate analytical sensitivity, and high analytical precision as well as user-friendly instrument care and maintenance.</p>
<p>Lastly, we will show results from oligonucleotides and proteins analyzed on LC/MS single quadrupole and Time of Flight (TOF) instruments, the latest scientific applications, and recent method improvements.</p>
<blockquote>
<p><strong>Presenter:</strong> Ian Edwards, Ph.D. (LC/TQ Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>Ian holds a PhD from the Centre for Proteome Research at the University of Liverpool. He has spent time as a pre- and post-sales MS applications specialist focused on MS imaging and proteomics, as a field marketing manager for -omics, and as a global pharmaceutical marketing manager. Ian joined Agilent recently as LC/TQ Product Manager.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Russell Burge, Ph.D. (LC/SQ and LC/TOF Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>Russell earned a PhD in biochemistry and molecular biology from Scripps Research. He has extensive experience in the R&amp;D of biomolecules and biopharmaceuticals, and the implementation of automated workflows. Russell has acted as a Product Manager for various products in Life Science and Industrial Markets, and he currently manages the LC/MS SQ and LC/MS TOF product portfolios at Agilent.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Christian Klein, Ph.D. (LC/Q-TOF Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>With an education in Chemistry, Chris Klein received his Ph.D. in 2005 at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. He joined Agilent Technologies in 2010 as the lead chemist in the LC/Q-TOF R&amp;D team. In 2018 Chris jointed the marketing team as Portfolio Product Manager, responsible for LC/Q-TOF and Ion Mobility.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Róisín Murtagh (Editor, Wiley)</p>
</blockquote>
<blockquote>
<p>Róisín Murtagh has been an editor for Wiley Analytical Science since 2021. She holds a science degree from Maynooth University, Ireland, and an MSc in Medicinal Chemistry from the Open University, UK. With a background encompassing over 10 years of experience in analytical science, she has actively contributed to both industry and academic research.</p>
</blockquote>


Wiley: Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

End-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.**

LCMS webináře se zaměřením na LC/TOF - strana 21